Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
DiaMedica Therapeutics Inc
NASDAQ DMAC
Data sourced from
and
and
DiaMedica Therapeutics Inc Return on Common Equity 3 year CAGR for the Trailing 12 Months (TTM) ending June 30, 2019
DiaMedica Therapeutics Inc Return on Common Equity 3 year CAGR is NA for the Trailing 12 Months (TTM) ending June 30, 2019. Return on common equity measures the profitability of a company relative to its common shareholders' equity. It is calculated by dividing the net income by the common stock (net). This ratio indicates how effectively a company generates profit for its common shareholders' equity investment. A higher return on common equity suggests better profitability and value creation for common shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: DMAC
| CEO | Mr. Dietrich John Pauls MBA |
| IPO Date | Jan. 4, 2008 |
| Location | United States |
| Headquarters | Two Carlson Parkway, Minneapolis, MN, United States, 55447 |
| Employees | 18 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Key trends
Similar companies
Milestone Pharmaceuticals Inc
NA
NA
Centessa Pharmaceuticals PLC ADR
NA
NA
Day One Biopharmaceuticals Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email